Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension

被引：0
|
作者：
Tikkanen, I. [1 ]
Narko, K. [2 ]
Zeller, C. [3 ]
Green, A. [4 ]
Salsali, A. [5 ]
Broedl, U. C. [5 ]
Woerle, H. J. [5 ]
机构：
[1] Helsinki Univ Cent Hosp, Minerva Inst Med Res, Dept Med, Helsinki, Finland
[2] Boehringer Ingelheim Finland Ky, Helsinki, Finland
[3] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
[4] InVentiv Hlth Clin, Maidenhead, Berks, England
[5] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
942
引用
收藏
页码：S377 / S377
页数：1
相关论文
共 50 条
  • [1] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes (T2DM)
    Kohler, Sven
    Salsali, Afshin
    Hantel, Stefan
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2015, 64 : A302 - A303
  • [2] Empagliflozin Monotherapy for 12 Weeks Improves Glycemic Control in Japanese Patients With Type 2 Diabetes (T2DM)
    Kadowaki, Takashi
    Haneda, Masakazu
    Inagaki, Nobuya
    Taniguchi, Atsushi
    Sakamoto, Masashi
    Koiwai, Kazuki
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2013, 62 : A297 - A298
  • [3] Empagliflozin Monotherapy Improves Glucose Control in Drug-Naive Patients With Type 2 Diabetes (T2DM)
    Roden, Michael
    Weng, Jianping
    Eilbracht, Jens
    Delafont, Bruno
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2013, 62 : A280 - A280
  • [4] Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM)
    Kohler, S.
    Kaspers, S.
    Salsali, A.
    Zeller, C.
    Woerle, H. -J.
    [J]. DIABETOLOGIA, 2016, 59 : S26 - S26
  • [5] Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Renal Impairment (RI)
    Barnett, Anthony H.
    Mithal, Ambrish
    Manassie, Jenny
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2013, 62 : A286 - A286
  • [6] Empagliflozin as Add-On to Metformin for 24 Weeks Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Broedl, Uli C.
    Woerle, Hans J.
    [J]. DIABETES, 2013, 62 : A282 - A282
  • [7] Empagliflozin as Add-On to Pioglitazone With or Without Metformin Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Kovacs, Christopher
    Seshiah, Veeraswamy
    Swallow, Ros
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2013, 62 : A291 - A291
  • [8] Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
    Tikkanen, Ilkka
    Narko, Kirsi
    Zeller, Cordula
    Green, Alexandra
    Salsali, Afshin
    Broedl, Uli C.
    Woerle, Hans J.
    [J]. DIABETES CARE, 2015, 38 (03) : 420 - 428
  • [9] Empagliflozin Improves 24-Hour Blood Pressure Profiles in Patients With Type 2 Diabetes and Hypertension
    Tikkanen, Ilkka
    Narko, Kirsi
    Zeller, Cordula
    Green, Alexandra
    Salsali, Afshin
    Broedl, Uli C.
    Woerle, Hans J.
    [J]. CIRCULATION, 2013, 128 (22)
  • [10] Blood Pressure (BP) Effects of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Pfeifer, Michael
    Townsend, Raymond
    Davies, Michael J.
    Vijapurkar, Ujjwala
    Ren, Jimmy
    [J]. DIABETES, 2016, 65 : A303 - A303
12345